CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed the intimation for loss of shares certificate22-05-2024
22-05-2024
Cipla gets USFDA nod to market Lanreotide injection
Lanreotide Injection is therapeutic equivalent generic version of Somatuline Depot Injection22-05-2024
CIPLA LTD. - 500087 - Cipla Receives Final Approval For The Generic Version Of Somatuline(r) Depot (Lanreotide) Injection
Cipla receives final approval for the generic version of Somatuline (R) Depot (Ianreotide) Injection22-05-2024
CIPLA LTD. - 500087 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Please find the attached Result of Postal Ballot and Scrutinizer''s report17-05-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrations Committee of the Company on 16th May 2024 has allotted 50,768 fully paid-up equity shares of INR 2 each, pursuant to exercise of ESOPs/ESARs under the ESOP scheme 2013-A and ESAR scheme 2021 of the Company. Consequently, the issued, subscribed and paid-up capital of the Company stands increased to INR 1,61,48,91,472 comprising of 80,74,45,736 equity shares of face value INR 2 each.17-05-2024
Cipla promoters sell 2.53% stake for Rs 2,751 crore
"Post transaction, the entire promoter group, including persons acting in concert, continues to hold 31.67% in the company and remains committed to the future of Cipla," the company said in a statement.16-05-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Acquisition
Cipla Limited has entered into definitive agreements on 15th May, 2024 for further investment of upto INR 26 crores in Achira Labs Private Limited, associate company.15-05-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We are enclosing herewith copy of the transcript of the Company''s Q4 FY24 earnings conference call dated 10th May 2024.15-05-2024
CIPLA LTD. - 500087 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samina Hamied & Others15-05-2024
CIPLA LTD. - 500087 - Clarification W.R.T. Sale Of Shares By The Promoter Group
Clarification w.r.t. sale of shares by the Promoter Group is enclosed.15-05-2024